Q32 Bio Prices $200M Stock Offering at $18.25, Shares to Dilute
QTTB has more than doubled off its 52-week low of $1.569 on elevated volume (2.8× avg).
Summary
Q32 Bio priced its $200 million public offering at $18.25 per share, a slight discount to the last close of $18.46. The deal includes 6.03 million common shares and pre-funded warrants for 4.93 million shares, with a 30-day greenshoe option for 1.64 million additional shares. This follows the positive Phase 2a bempikibart data on July 13, which likely enabled the raise. The offering is highly dilutive—total shares outstanding could increase by roughly 50% if the greenshoe is exercised. Proceeds will fund bempikibart's advancement into later-stage trials and for working capital. The offering is expected to close on or about July 16.
At the time of this announcement, QTTB was trading at $18.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $437.2M. The 52-week trading range was $1.57 to $23.57. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: PR Newswire.